علاج متلازمة لامبرت-إيتون الوهنية العضلية من الخط الأول

References

• GKS must be used for the treatment of LEMS as a basic immunotherapeutic agent at a dosage appropriate to the severity of the disease for as short a period as possible, taking into account comorbidities, contraindications, and side effects.
• AZA must be used for steroid-sparing therapy.
• As with MG, based on expert knowledge, the recommendation is to initially start a combination therapy of GKS and AZA.
• The specific recommendations for dosing and therapy monitoring are analogous to MG.
• The therapy should be started with 25–50 mg daily in the first week and then gradually increased over 3–4 weeks under regular laboratory control.
• An absolute lymphocyte count of 600–1000/μl is targeted during therapy.